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Abstract
Background: Development of a potent vaccine adjuvant without introduction of any side effects remains an unmet
challenge in the field of the vaccine research.
Methodology/Principal Findings: We found that laser at a specific setting increased the motility of antigen presenting cells
(APCs) and immune responses, with few local or systemic side effects. This laser vaccine adjuvant (LVA) effect was induced
by brief illumination of a small area of the skin or muscle with a nondestructive, 532 nm green laser prior to intradermal (i.d.)
or intramuscular (i.m.) administration of vaccines at the site of laser illumination. The pre-illumination accelerated the
motility of APCs as shown by intravital confocal microscopy, leading to sufficient antigen (Ag)-uptake at the site of vaccine
injection and transportation of the Ag-captured APCs to the draining lymph nodes. As a result, the number of Ag
+ dendritic
cells (DCs) in draining lymph nodes was significantly higher in both the 1u and 2u draining lymph nodes in the presence
than in the absence of LVA. Laser-mediated increases in the motility and lymphatic transportation of APCs augmented
significantly humoral immune responses directed against a model vaccine ovalbumin (OVA) or influenza vaccine i.d. injected
in both primary and booster vaccinations as compared to the vaccine itself. Strikingly, when the laser was delivered by a
hair-like diffusing optical fiber into muscle, laser illumination greatly boosted not only humoral but also cell-mediated
immune responses provoked by i.m. immunization with OVA relative to OVA alone.
Conclusion/Significance: The results demonstrate the ability of this safe LVA to augment both humoral and cell-mediated
immune responses. In comparison with all current vaccine adjuvants that are either chemical compounds or biological
agents, LVA is novel in both its form and mechanism; it is risk-free and has distinct advantages over traditional vaccine
adjuvants.
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Introduction
Vaccine adjuvants are traditionally defined as chemical
compounds or macromolecules that augment immune responses
of co-administered antigen (Ag) with minimal toxicity or long
lasting immunity on their own. These agents target innate
immune responses through two major mechanisms. Adjuvants
like aluminum salts, oil-in-water emulsions, and liposomes
facilitate Ag depot and thus Ag-uptake by antigen presenting
cells (APCs). Other adjuvants like monophosphoryl lipid A (MPL),
CpG, or poly I:C, activate APCs by binding to Toll-like receptors
[1]. All these adjuvants cause inflammation at the site of injection
and with local reactogenicity, and many of them also have a
potential for long term side effects and therefore have not been
approved for human use. The most widely used adjuvant in the
clinics has been aluminum-based mineral salts (alum) over the
past 80 years [2].
Alum has a good track record of safety and has been widely and
successfully used in many licensed vaccines [3]. However, some
limitations of alum have been described. For instance, it is a rather
weak adjuvant when used with certain types of vaccines like
influenza hemaggulutinin (HA) antigens [4], typhoid vaccine [5],
Haemophilus influenzae type b (Hib) capsular polysaccharide
conjugated to tetanus toxoid [6], or recombinant protective
antigen of anthrax after freezing [7]. Alum appears to be potent in
primary immunizations, but has a limited ability to boost humoral
immune responses in second and third doses [8]. It also affects
little in cell-mediated immunity and induces primarily Th2
immune responses [3]. Moreover, while alum adjuvant causes
some low level local reactogenicity in most of vaccinees, it has been
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received intramuscular alum-adjuvanted vaccines in France [9]. In
addition to side effects, alum is a non-crystalline gel and antigen
must be adsorbed onto the highly charged aluminum particles for
the adjuvant to be potent. At least two serious effects result from
use of alum. First, freezing, lyophilization or cold storage that
results in separation of antigen from the aluminum particles would
cause a loss of the adjuvant potency [10–12]. Secondly, the
biophysical structure and stability of the resultant product are
difficult to assay as an alum complex. Therefore, alternative
vaccine adjuvants that are non-toxic, consistently effective, and
easily used have been hunted for in the past thirty years.
Lasers have been applied to medicine for decades, and their
therapeutic potential is still being actively explored. Conventional
medical applications of lasers with a high power have largely been
designed to destroy unwanted tissues, such as laser surgery, laser
ablation or thermotherapy. Photodynamic therapy kills cancer
cells via photoreactive compounds [13], which stimulates long-
term, systemic tumor immunity and eradicate distal tumors in
some cases [14]. Low-power lasers are used to seal blood vessels or
‘‘weld’’ tissues together, to accelerate the healing of wounds and
burns [15;16] or to modulate immune responses as adjuvant
therapy [17]. Research on the use of laser to boost immunization
has been very limited. Femtosecond laser was shown to sufficiently
enhance DNA delivery into cells and induce immune responses to
the encoded antigen [18]. Onikienko and colleagues reported in a
Russian journal that pre-illumination of skin with a pulsed copper
vapor laser at a high power (0.6 W) enhanced humoral immune
responses provoked by vaccines i.d. injected at the site of laser
exposure in a manner dependent on heat shock protein (HSP)-70
and inflammatory cytokines [28].
The current investigation aims at the development of a
practical, safe laser vaccine adjuvant (LVA) capable of boosting
both humoral and cell-mediated immune responses against
protein-based vaccines, with few side effects. We show here that
brief laser illumination at a specific laser setting increases the
mobility of APCs and thus an efficacy of antigen capture by the
cells, without incurring any inflammation or reactogenicity. Laser-
mediated increases in antigen capture by APCs greatly strength-
ened humoral and cell-mediated immune responses against either
a model or a clinical vaccine. LVA represents a novel, potent
vaccine adjuvant with few side effects.
Materials and Methods
Mice
Male BALB/c mice at 6–8 weeks of age were purchased from
Charles River Laboratories (Wilmington, MA). MHC II-EGFP
mice expressing MHC class II molecule infused into enhanced
green fluorescent protein were a kindly gift of Drs. Boes and
Ploegh [19]. All mice were housed in conventional cages in the
animal facilities of Massachusetts General Hospital (MGH) in
compliance with institutional guidelines. The study was reviewed
and approved by the MGH Subcommittee of Research Animal
Studies.
Devices
A Q-switched 532-nm Nd:YAG laser with a pulse width 5–7 ns,
beam diameter 7 mm, and frequency 10 Hz was used in the study
unless otherwise indicated (Spectra-Physics Inc., Mountain View,
CA). Average output powers were measured by a power meter
(Ophir Optics, Inc., MA) prior laser illumination. Skin tempera-
ture (Tm) was monitored during laser illumination by an infrared
camera focusing on the center of the illumination area (FLIR
Systems, Boston, MA).
Immunizations
Mice were anesthetized by intraperitoneal (i.p.) injection of a
mixture of ketamine (80 mg/kg) and xylazine (20 mg/kg) and the
lower dorsal hair of the mice was removed by shaving and a hair
removal lotion (Church&Dwight Co.). The skin was exposed next
day to laser for 2 min at 0.3 W unless otherwise indicated after the
mice were anesthetized similarly. The mice were then immunized
by intradermal (i.d.) administration into the laser-illuminated site
with either an indicated dose of ovalbumin (OVA, Grade V,
Sigma, St. Louis, MO) or 2009–2010 seasonal influenza (flu) virus
vaccine (Fluvirin, Novartis). Mice in control groups were treated
and immunized similarly except for no laser illumination. In some
experiments, OVA solution was passed through a Detoxi-Gel
column to remove contaminated endotoxin according to the
manufacturer’s instruction (Thermo Scientific, Rockford, IL).
Effects of laser on a booster vaccination were evaluated with flu
vaccine by vaccination at the contralateral site following laser
illumination at an interval of 3 weeks. To determine the effect of
skin Tm on laser-mediated immune enhancement, skin Tm was
maintained at 42uCb ya1 0 6106100 mm
3 steel bar that was
vertically immersed in a 44uC water bath with its top 1 cm above
the water surface. After warming the skin for 2 min, the mice were
immunized at the warm skin with OVA as above. In a separate
series of experiments aimed at addressing laser adjuvant effects on
intramuscular (i.m.) vaccination, a hair-like optical fiber with a 5-
mm diffusing tip coated with ZnO-Epoxy resin was inserted
perpendicularly into the posterior thigh muscle and lighted up by a
long-pulsed laser (KTP/532 nm, Aura; Laserscope, San Jose, CA)
at 0.3 W for 1 minute followed by i.m. vaccination of 50 mg OVA.
Blood collection and serum antibody titer detection
Blood samples of ,30 ml were collected by nicking the tail vein
before or at the indicated times after immunization. Serum was
prepared by centrifugation to remove the cells and kept at 280uC
till analysis. Serum antigen specific IgG levels were detected by
ELISA (Enzyme-linked immunosorbent assay) with 100 mg/ml
OVA or 1 mg/ml Flu vaccine as a coating antigen (Ag). Antibody
(Ab) titer was determined by the dilution factor with an OD490 nm
absorbance $0.2. No mice receiving laser illumination only or
before immunization had detectable levels of antibody directed
against OVA or flu vaccine during the course of this study.
Intravital confocal imaging
The posterior thigh skin of MHC II-EGFP transgenic mice was
either left untreated or exposed to laser for 2 min at 0.3 W,
followed by i.d. injection of endotoxin-free OVA or PBS as
controls. Dermal GFP
+ cells were imaged 5 hrs later by intravital
confocal microscopy, during which body Tm was maintained at
36uC. Every twelve overlapping images of dermal GFP
+ cells at
the site of immunization or laser illumination were acquired and
merged into single large-field images using Photoshop CS3.0
software. To analyze the migratory ability of APCs, the time lapse
images of dermal GFP
+ cells at a specific area were acquired every
30 seconds for 20 minutes and pseudopods of about 30 randomly
selected cells were tracked individually by Image J software.
Detection of Ag-captured dendritic cells (DCs)
To determine the number of Ag-captured DCs in the skin,
fluorescently labeled OVA (Alexa Fluor 647-conjugated OVA or
AF647-OVA) was i.d. injected into the laser-exposed skin as above.
Laser and Motility of DCs
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2 at the site of Ag-
injection was excised 6 or 24 hrs later, washed thoroughly, cut into
small pieces, and digested in 0.2% collagenase D (Roche
Diagnostics, Mannheim, Germany) supplemented with 0.6 U/ml
dispase (Gibco, Invitrogen, Carlsbad, CA) and 2% fetal bovine
serum (FBS) in PBS at 37uC for 2 hr with intermittent vortexing.
Single cell suspensions were prepared by passing the digest
through a 40-mm cell strainer and stained with anti-CD11c
antibody (N418) (eBioscience, San Diego, CA), a marker for DCs.
The number and percentage of CD11c
+AF647-OVA
+ cells on
gated CD11c
+ cells were acquired on FACSAria equipped with
FACSDiva software (Becton Dickinson) and analyzed using
FlowJo software. To evaluate the number of Ag-captured DCs
in the lymph node (LN), LNs were dissected and minced against a
40-mm cell strainer. The number and percentage of CD11c
+
AF647-OVA
+ cells were analyzed as above.
Measurement of cell-mediated immunity
CD4+ T cell-mediated immunity was evaluated in mice three
weeks after primary immunization with OVA at the laser-exposed
site or OVA alone. Ag-specific T cells were activated by i.p.
injection of 40 mg OVA and expanded in vivo for one week.
Splenocytes were isolated and stimulated with 50 ng/ml PMA and
750 ng/ml ionomycin in the presence of 0.1% Golgi-Plug for
5 hrs at 37uC with 5% CO2. Cells were then stained with PE-anti-
CD4 (GK1.5), fixed, and permeabilized in a permeabilization
buffer per the manufacturer’s instruction, followed by staining with
Alexa Fluor 647-anti-IL4 (11B11) and FITC-anti-IFNc
(XMG1.2). Alternatively, cell-mediated immunity against OVA,
including both CD4
+ and CD8
+ T cells, was assessed three weeks
after primary immunization by in vitro stimulation assays. Briefly,
popliteal draining LNs were isolated and total cells were counted
and stimulated overnight with 10 mg/ml OVA, 4 mg/ml anti-
CD28 monoclonal antibody 37.51 (BD Bioscience Pharmingen,
San Diego, CA). The stimulation continued for another 6 hrs after
addition of 0.1% Golgi-Plug to the culture. The stimulated cells
were stained with FITC-anti-CD4 (GK1.5) or PerCP-Cy5.5-anti-
CD8 (53-6.7), fixed, and permeabilized, followed by staining with
anti-IL4 and anti-IFNc as above. The numbers of CD4
+IL4
+ and
CD4
+ IFNc
+ cells or CD8
+IL4
+ and CD8
+IFNc
+ cells were
analyzed on FACSAria and expressed as absolute numbers of
CD4
+IL4
+ and CD4
+IFNc
+ cells or CD8
+IL4
+ and CD8
+IFNc
+
per LN. All the reagents were purchased from Biolegend, San
Diego, CA unless otherwise indicated.
Histological examination
The lower dorsal skin of mice was exposed to laser for 2 min at
0.3 W or i.d. injected with 10 ml alum adjuvant (Imject Alum,
Thermo Scientific, Rockford, IL). Full thickness of the skin at the
site of laser illumination or alum injection was excised after 2 hrs
or 1 or 3 days, fixed in 10% formalin and subjected to a standard
histological examination.
Quantitative real-time PCR
To analyze inflammatory cytokine gene expression following
laser illumination, the full thickness of the skin area about
767m m
2 was excised 6 hrs after laser illumination for 2 min at
0.3 W or alum injection as above. Total RNA was extracted,
reverse-transcribed, and amplified by real-time PCR using a
SYBR Green PCR kit (Applied Biosystems, Foster City, CA) on an
Mx4000
TM Multiplex Quantitative PCR System (Stratagene).
Threshold cycle (Ct) was used to calculate the relative template
quantity as the manufacturer’s recommendation using b-actin as
an internal control. The basic gene expression level was set at 1
when analyzing the data. The primers used were: forward,
CCCTCACACTCAGATCATCTTCT and reverse, GCTAC-
GACGTGGGCTACAG for TNFa; forward, GCAACTGT-
TCCTGAACTCAACT and reverse, ATCTTTTGGGGTC-
CGTCAACT for IL-1b; forward, TAGTCCTTCCTACCC-
CAATTTCC and reverse, TTGGTCCTTAGCCACTCCTTC
for IL-6; forward, TTAAAAACCTGGATCGGAACCAA and
reverse, GCATTAGCTTCAGATTTACGGGT for CCL2; and
forward, GGCTGTATTCCCCTCCATCG and reverse, CCAG-
TTGGTAACAATGCCATGT for b-actin.
Statistical analysis
Student t-test or one-way ANOVA was used to analyze the
difference between groups or among multiple groups, respectively.
P values were calculated by PRISM software (GraphPad, San
Diego, CA).
Results
Determination of a safe laser setting
To define a laser setting that could boost immune responses
without incurring any tissue damage, skin temperature was
monitored by an infrared camera during light illumination, as
the photothermal reaction is considered to be the primary cause
for laser-induced tissue damage. Skin temperature rose with
increasing output powers of laser and times of illumination.
Average output powers of 0.6 W or higher damaged skin instantly,
evidenced by skin whitening and shrinkage, concurrent with
elevation of skin temperature to 50uCo r6 0 uC, respectively, in less
than a minute (Figure 1A). On the contrary, an output power of
0.3 W or lower did not raise the skin temperature higher than
41uC or cause discoloration of the skin visibly even for an extended
period of illumination (Figure 1A). Laser illumination at 0.3 W for
2 min, 90 J/cm
2 also caused little alteration in tissue histology at
the site of illumination when examined on day 0, 1 or 3 post
illumination (Figure 1B). In accordance to this, we observed, on a
high resolution, no overt cell death or leukocyte infiltration in
these tissue samples. In contrast, an output power of 0.4 W or
higher damaged tissues with apparent cell death in the epidermis
and was thus precluded from our studies. In parallel studies,
intradermal administration of alum adjuvant stimulated vigorous
infiltration of leukocytes into both dermal and subcutaneous tissues
as early as 2 hrs (day 0), which was persistent for weeks,
concurrent with the production of high levels of inflammatory
cytokines such as IL-1b, IL6, and CCL2 (Figure 1B and C). No
increases in the expression of inflammatory cytokines including
TNFa, IL-1b, IL6, and CCL2, were observed by laser
illumination when compared to controls (Figure 1C).
Laser enhances the motility of APCs
APCs are the primary targets for most of adjuvants [1]. We
therefore addressed whether this non-inflammatory, safe laser
could affect the activity of skin APCs. To this end, APCs in MHC
II-EGFP transgenic mice were tracked by intravital confocal
microscopy after 5 hrs of laser illumination for 2 min at 0.3 W
[19;20]. Intravital imaging of the dermal layer, where a majority of
antigen was taken up by APCs following i.d. administration,
revealed that a majority of APCs formed discernible cell islands or
clusters in the control (Figure 2A). These cell clusters appeared to
be dispersed into single cells spreading evenly following laser
illumination (Figure 2A). While OVA injection also provoked cell
spreading, the degree of dispersion seemed much less prominent as
compared to that seen with laser illumination. A combination of
laser and OVA further dispersed the cells, as reflected by a drastic
Laser and Motility of DCs
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with a great decrease in the number of cell clusters over OVA
alone (Figure 2A).
To address whether laser-induced redistribution of APCs was
ascribed to increased cell motility, we tracked the behavior of
APCs in the dermal layer 5 hrs after laser illumination by
acquiring the time-lapse images of individual cells every 30
seconds for total 20 minutes with intravital confocal microscopy.
Dermal GFP
+ cells, mostly DCs and macrophages, were
constantly changing their cell shapes, albeit slowly, and extending
pseudopods for environmental surveillance, but most of them
remained at their original locations during a 20 min period of
recording in the control (Figure 2B, 1
st panel). On the contrary,
the cells in the laser-treated mice showed a high migratory ability,
moving away from their original locations during the same period
of time, as indicated by an increased distance between arrows and
the individual cells over times (Figure 2B, 2
nd and 4
th panels).
OVA injection also increased migration of APCs, albeit to a lesser
extent (Figure 2B, 3
rd panel). Strikingly, when OVA was
administrated into the site of laser illumination, a synergistic effect
was observed on APC motility. Quantification of the cell motility
by tracking of randomly selected 30 cells revealed that laser
illumination alone increased pseudopod mobile velocity, a rate of
change in their position regardless of direction over to time, from
2.2660.09 mm/min in the control, to 3.3560.09 mm/min in the
laser-treated skin (Figure 2C, p,0.001). When laser treatment was
combined with OVA immunization, the pseudopod mobile
velocity was accelerated to 4.2960.13 mm/min, which was
significantly higher than 2.7860.07 mm/min observed with
OVA alone (p,0.001). Likewise, the cell pseudopod migratory
speed as measured by a traveling distance per min was faster with
laser illumination irrespective of whether or not OVA was
administered (0.7160.08 vs. 0.2360.03 mm/min in the absence
of OVA and 0.7660.08 vs. 0.3160.03 mm/min in the presence of
OVA, p,0.001) (Figure 2D). Consequently, over 64% of APC
pseudopods in the laser-treated or laser+OVA-treated groups had
a migratory speed above 0.5 mm/min, whereas less than 10% of
pseudopods in control and OVA alone groups showed a migratory
speed above 0.5 mm/min (Figure 2D). Similar increases in the
motility of APCs were observed in 0.5 or 16 hr, but not at 24 hr,
after laser illumination, which probably occurred upon laser
illumination (data not shown).
Laser illumination enhances Ag-uptake by skin DCs
A significant increase in the motility of APCs resulting in a high
number of single APCs in the dermis was expected to augment Ag-
uptake at the site of Ag injection. To address this, 0.5 mg
fluorescently labeled OVA (AF647-OVA) was i.d. administered
into laser-exposed skin, followed by flow cytometric analysis of
CD11c
+AF647-OVA
+ cells at the Ag-injection site (Figure 3A).
While percentages of Ag
+DCs were increased proportionally with
the amounts of OVA injected, significantly higher levels of
Ag
+DCs were consistently attained at 6 hrs after laser illumination
and/or Ag injection, in the laser-treated group than in non-treated
group at all antigen concentrations tested (Figure 3A&B). At the
lowest Ag concentration, approximately 50% of DCs had taken up
the Ag at laser-treated site as compared to 27% of Ag
+DCs in non-
illuminated control (Figure 3A&B). A similar increase in the
Figure 1. No significant alteration in skin histology after laser illumination for 2 min at 0.3 W. The lower dorsal skin of mice was exposed
to laser at indicated output powers and times. Skin Tm was monitored during the exposure by an infrared camera (A). Histological examination was
performed after 2 hrs (D0), 1 day (D1) or 3 days (D3) in the skin that was either illuminated with laser for 2 min at 0.3 W or i.d. injected with alum
adjuvant (10 ml) or PBS as controls (B). Full thickness of skin tissues treated for 6 hrs as in B was evaluated for inflammatory cytokine expression by
real-time RT-PCR (C). Scale bar in B, 100 mm. Data are representative of at least three experiments with similar results in A and B. Data in C are the
means 6 standard errors of the mean (SEM) of six samples. **, p,0.01.
doi:10.1371/journal.pone.0013776.g001
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+ CD11c
+ cells was also observed in 24 hrs
(Figure 3D). Not only did a high proportion of DCs capture the Ag
but also more Ag was taken up by individual DCs owing to laser
pre-illumination, manifested by a significantly higher level of OVA
mean fluorescent intensity (MFI) in individual cells at all Ag
concentrations tested (Figure 3C&E). The Ag-uptake activity of
DCs was light-dose dependent (Figure 3F&G): the longer
illumination was and the higher Ag-uptake activity resulted.
Notably, percentages of Ag
+DCs and MFI of AF647-OVA were
reduced at 24 hr as compared to 6 hr in both laser-treated and
control groups, presumably due to DC emigration as well as
antigen processing during this period of time. Despite an increase
Figure 2. Laser increases the mobility of dermal APCs. A. Altered distribution of dermal APCs after laser illumination. Distribution of dermal
APCs in MHC-II EGFP transgenic mice was analyzed by intravital confocal microscopy after 5 hrs of laser illumination for 2 min at 0.3 W with or
without OVA administration. Scale bar: 200 mm. B. Increased motility of individual cells after laser illumination. Representative time-lapse images
demonstrated migratory behaviors of dermal APCs within a 20 minute period of recording: arrows indicate the original location of the cell. C and D.
Quantification of cell motility affected by laser illumination. Mean mobile velocity (C) or migratory speed (D) of randomly selected pseudopods was
imaged in 5 hrs after laser illumination and OVA injection and analyzed by Image J software. Each symbol represents data of a single pseudopod.
n=31.
doi:10.1371/journal.pone.0013776.g002
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+ CD11c
+
cells. Single cell suspension was prepared from full thickness of the skin 6 hrs after 0.5 mg AF647-OVA in 20 mlo r2 0ml PBS was i.d. administrated into
the site of laser illumination or control. The cells were stained with anti-CD11c antibody, and analyzed for percentages of OVA
+CD11c
+ cells on the
gated CD11c
+ cell population. Percentages of OVA
+ CD11c
+ cells (B and D) and mean fluorescence intensity (MFI) of AF647-OVA (C and E) were
analyzed at 6 hr (B and C)o r2 4h r( D and E) after i.d. administration of AF647-OVA at the indicated doses. n=6, blank bar, AF647-OVA alone; and
black bar, laser + AF647-OVA. F and G. A light dose-dependent increase in Ag-uptake by DCs. The lower dorsal skin of mice was illuminated with laser
at 0.3 W for the indicated time, corresponding to a light dose of 11.3, 22.5, 45, or 90 J/cm
2, respectively. AF674-OVA at 2 mg/ mouse was injected into
the laser-illuminated site and 6 hrs later, percentages of OVA
+ CD11c
+ cells (F) and MFI of AF647-OVA (G) were analyzed and expressed as above.
* and **, p,0.05 and 0.01, respectively.
doi:10.1371/journal.pone.0013776.g003
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+CD11c
+ cells, we did not observe a
significant difference in the percentage of CD11c
+ cells with or
without laser treatment (data not shown), suggesting that DC
influx is unlikely to contribute to the increased number of
OVA
+CD11c
+ cells, in agreement with a highly precise nature of
laser.
Laser illumination enhances Ag-uptake in draining lymph
nodes
Consistent with an increase in the motility and Ag-uptake of
DCs in the skin after laser illumination, the number of Ag
+DCs in
the draining lymph nodes (LNs) was also significantly greater at 6
or 24 hr after varying concentrations of OVA were administered
into the site of laser illumination than into a non-illuminated
control site (p,0.01, Figure 4). Strikingly, an almost 5-fold
increase in the number of OVA
+ DCs was observed in the
secondary axillary draining LN in LVA-treated group as
compared to non-LVA controls (Figure 4D), presumably due to
either the enhanced free antigen flow and/or the enhanced
migration of Ag+DCs to the 2u draining LN by laser illumination
(Figure 4B vs 4C). Only a few basal Ag-uptake DCs were seen in
contralateral or mesenteric LNs, which were not affected by laser
illumination (data not shown).
Laser augments and prolongs humoral immune
responses
Immune effects of this safe laser were next evaluated using a
model antigen OVA. Laser illumination at 0.3 W for 2 min with a
dose of 90 J/cm
2 boosted OVA-specific antibody (Ab) production
by 300,500% over intradermal OVA injection alone (Figure 5A,
p,0.001). The high titer of antibody production was sustained for
more than 15 weeks following a single immunization (Figure 5A).
Production of OVA-specific Ab was proportionally elevated with
an increasing laser dose up to 90 J/cm
2, reaching a plateau
between 90,180 J/cm
2 (Figure 5B), in agreement with the light
dose-dependent Ag-uptake activity of dermal DCs (Figure 3F).
Similar laser adjuvant effects were also observed when endotoxin-
removed OVA was used for immunization (data not shown), ruling
out that the immune-enhancing effect was attributed in part to
endotoxin contamination. Cell-mediated immunity against OVA
was also assessed by analysis of CD4
+IL4-secreting splenocytes in
these mice. Mice receiving laser plus OVA produced a
significantly higher number of CD4
+IL4-expressing cells than
mice immunized with OVA alone (Figure 5E, p,0.001). But, no
such an increase was observed in IFN-c-secreting CD4
+ or CD8
+
T cells with this low-power laser illumination in the animals
regardless of whether the specific T cells were stimulated and
Figure 4. Laser increases Ag-uptake by DCs in the draining lymph node. A. Representative flow cytometry profiles showing the number of
OVA
+CD11c
+ cells. Single cell suspensions were prepared from the draining LN (inguinal) after 6 or 24 hrs of laser illumination and i.d. injection of
10 mg AF647-OVA. The cells were stained with anti-CD11c antibody and analyzed as Figure 3. The absolute numbers of CD11c
+OVA
+ cells were given
in the profile in one million cells counted. B and C. An increase in the number of Ag-captured DCs in the 1u draining LNs. The cells were prepared
from the inguinal LN at 6 hr (B)o r2 4h r( C) after laser illumination and AF647-OVA injection at the indicated dose and analyzed as above. Data are
means 6 SEM of absolute numbers of CD11c
+OVA
+ cells in 10
4 LN cells from draining lymph nodes analyzed as A. n=6; blank bar, AF647-OVA alone
and black bar, laser + AF647-OVA. D. An increase in the number of Ag-captured DCs in the 2u draining LN at 24 hrs after 10 mg AF647-OVA was i.d.
administered. The cells isolated from the ipsilateral axillary LN were analyzed and the data were expressed as above.
doi:10.1371/journal.pone.0013776.g004
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Th1 immune responses were observed when an increase in a light
dose .180 J/cm or an output power .0.3 W was applied prior to
i.d. administration of OVA, concomitant with some tissue damage
that was self-resolved in two or three days (data not shown).
We noted that although laser illumination elevated skin
temperature, laser-mediated immune enhancement was not solely
ascribed to the photothermal effect. As shown in Figure 5C, when
the skin area of 1 cm
2, a size that is larger than that of the laser
beam (0.4 cm
2), was warmed to 42uC with a metal bar for 2 min
followed by antigen injection as above, OVA-specific Ab
production was increased only by 20%. Moreover, if antigen
was injected into a distal site (indirect), for instance, 1 cm away
from the laser-illuminated site, the immune-enhancing potential
decreased substantially (Figure 5D). Thus, Ag delivery directly into
the site of laser illumination is a key.
Laser augments not only primary but also booster
immune responses against flu vaccine
To test immune-enhancing effects of LVA on a clinically
approved vaccine, the newest season flu vaccine (2009–2010) was
evaluated for both primary and booster immunizations. Laser pre-
illumination enhanced the production of flu-specific antibody by
400% in primary vaccination (Fig. 6A, p,0.01) and by 900% in a
booster immunization compared to vaccine control (Fig. 6B,
p,0.001). The synergistic enhancement of specific antibody
production in the second immunization over the first one is
pivotal for flu vaccines as most people receive flu vaccines annually
Figure 5. Laser enhances humoral immune response induced by OVA. A. Laser significantly augments and prolongs the production of
serum OVA-specific antibody. Serum OVA-specific antibody was detected at indicated times after i.d. injection of 40 mg OVA with (filled) or without
laser illumination (blank). B. A light-dose dependent augmentation of OVA-specific antibody production. The lower dorsal skin of mice received an
increasing laser dose from 11.3 to 22.5, 45, 90, or 180 J/cm
2, which corresponded to irradiation at 0.3 W for 0.25, 0.5, 1, 2, and 4 min, respectively. C.
Immune-enhancement effect of laser cannot be recapitulated with a Tm rise in the skin. Heat: the skin was warmed with a 42uC metal rod for 2 min
mimicking the Tm rise caused by laser illumination as described in Materials and Methods. D. Laser-mediated immune enhancement is area-
restricted. A significant increase in OVA-specific antibody production was attained only when OVA was injected into the illuminated site (direct) but
not in a distal site (indirect). Serum Ab titers were measured 3 wks after immunization in B,D. E. Laser increases the number of CD4
+IL4-secreting T
cells. T cells of OVA-immunized mice were activated in vivo for one week by i.p. injection of 40 mg OVA. CD4
+IL4-secreting cells were analyzed by flow
cytometry after surface staining with anti-CD4 antibody and then intracellular staining with anti-IL-4 antibody. Data are expressed as means 6 SEM of
absolute numbers of CD4
+IL4
+ cells in 10
4 CD4
+ splenocytes. n=6 for each group except for B in which 3 mice were used in each time point. *, **, ***,
p,0.05, 0.01, and 0.001, respectively, using one-way analysis of variance (ANOVA) in C and D, and student t-test in A and E.
doi:10.1371/journal.pone.0013776.g005
Figure 6. Laser enhances flu vaccine-induced immune respons-
es in both primary and booster immunizations. Laser augments
not only primary (A) but also booster (B) immune responses. Flu-
specific antibody was measured by ELISA at 3 weeks after the primary
immunization with 0.3 mg flu vaccine at the site of laser illumination or
control as Figure 5 (A). A booster immunization was carried out at the
contralateral side similarly three weeks later after blood collection for
assessing primary immune responses. Flu-specific antibody was
detected in two weeks as above (B). Each symbol represents the data
from individual mice. **, P,0.01; and ***, P,0.001.
doi:10.1371/journal.pone.0013776.g006
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reaction among new and previous flu vaccines.
LVA enhances both humoral and cell-mediated immunity
induced by intramuscular immunization
The majority of current vaccines are intramuscularly adminis-
tered. In an attempt to explore the universal use of the LVA, we
tested whether laser could enhance immunity induced by i.m.
immunization. To illuminate muscle, a hair-like diffusing optical
fiber was made in house by coating ZnO-Epoxy resin at the tip
about 5 mm in length, and inserted into the posterior thigh
muscle. The optical fiber was then lighted up by 18 ms, 2 Hz at
0.3 W for 1 min equivalent to 45 J/cm
2 on the skin, after which
OVA was i.m. administered slowly into the illuminated muscle.
Control mice received the same procedure except for not lighting
up the optical fiber after its insertion. A significant increase in the
production of OVA-specific Ab was attained by laser illumination
of muscle over non-treated muscle at a level resembling that seen
with i.d. vaccination (Figure 7A). In marked contrast, however, an
increase in Th1 immune responses was observed following laser
illumination of muscle prior to i.m. vaccination (figure 7). The
numbers of IFNc-producing CD4
+ and CD8
+ T cells were 717 or
328, respectively, in the draining LN, which represent a 100%
increase for CD4
+ cells or 277% for CD8
+ T cells over Ag alone
(Figure 7C and 7E). Laser illumination prior to vaccination also
resulted in a greater number of IL4
+-producing CD4+ and CD8
+
T cells as compared to Ag alone (Figure 7B and 7D). The results
demonstrate the ability of LVA to boost cell-mediated, in
particular, CD8+ T cell mediated immune responses.
Discussion
This investigation provides proof of concept evidence that brief
illumination of skin or muscle with non-destructive, safe, green
laser can prime the body to a stronger response to a protein
prototype vaccine that, by itself, induces relatively weak immune
responses. Although augmentation of humoral immune responses
by LVA was comparable or might be slightly inferior to alum
adjuvant (data not shown), LVA caused little toxicity, local
inflammation or reactogenicity, whereas alum adjuvant induced
vigorous inflammation, concurrent with skin rash and redness that
were persistent for weeks. Foremost, LVA boosts Th1-mediated
immune responses that are critical for protection against diseases
caused by intracellular pathogens such as viruses, parasites and
mycobacterium when applied intramuscularly. In contrast, alum-
based vaccine adjuvant has little effect on CD8+ T cell immune
responses [3;8]. In addition, LVA does not involve administration
of any foreign or self substance into the body apart from the
antigen itself so that no adjuvant-related complex can be formed
with host tissue even after repeated uses, by which a self-
destructive immune cross-reaction, also called ‘‘molecular mimic-
ry’’ that can potentially cause long-term side effects, can be
effectively prevented. On the contrary, with few exceptions, other
adjuvants are foreign to the body and have the potential to cause
adverse reactions in the long term if routinely used, in addition to
their local inflammation and reactogenicity [21–23]. Apart from
side effects, LVA is not a chemical or a compound and thus there
is no need of a specific formulation procedure to attain a stable
mixture between a specific Ag and an adjuvant. Yet, all current
vaccine adjuvants require an optimal formulation between vaccine
and adjuvant which must be demonstrated to meet pre-
determined specifications as physical and biological stability.
Meeting these requirements continues to be challenging for some
vaccines. For instance, mixing the new circumsporozoite protein
antigen RTS with AS04 unexpectedly blocked protective immu-
nity even though RTS in an oil-in-water emulsion containing
MPL induced protection against infection of Plasmodium falciparum
[24]. Thirdly, the laser ‘‘adjuvant’’ can be used immediately and
unlimitedly at any time, and does not require cold chain storages.
This benefit is of particular significance in preparing for an
outbreak of a new strain or flu pandemic such as the 2009
emergence of H1N1 or for biological attacks owing to their
unpredictability in both the scale and the timing. Finally, LVA
may be effective as a universal co-adjuvant, because there is no
direct interaction between ‘‘adjuvant’’ and a vaccine.
The mechanism whereby laser pre-illumination augments
immunity is completely novel and incompletely understood; one
clear effect is the enhancement of the mobility of APCs,
concomitant with little inflammation. An increase in the motility
of these long branching dendrites of APCs promotes them to
survey a greater area of the skin, thereby facilitating their antigen
sampling as reflected by an increase in the number of AF670-
Figure 7. Laser enhances cell-mediated immune responses
induced by i.m. immunization. The posterior thigh muscle of BALB/c
mice was illuminated by a 532-nm laser (KTP/532) delivered by a hair-
like diffusing optical fiber followed by i.m. vaccination with 50 mg OVA
(laser). Control groups received OVA immunization similarly without
laser illumination (control). OVA-specific antibody (A) and IL4- and IFNc-
secreting CD4
+ and CD8
+ cells in the dLNs were analyzed three weeks
later. OVA-specific Ab in the plasma was detected by ELISA as figure 5.
The numbers of IL4
+-secreting CD4
+ (B) and CD8+ cells (D) and IFNc
+-
producing CD4
+ (C) and CD8
+ (E) cells per LN were identified by flow
cytometric analyses after surface staining with anti-CD4 or anti-CD8
antibody followed by intracellular staining with anti-IL4 or anti-IFNc Ab.
n=6, **, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0013776.g007
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+DCs and MFI of OVA in individual cells at the site of
injection. This unique behavior of DCs has been previously
described as dendrite surveillance extension and retraction cycling
habitude (dSEARCH) [25]. The increased motility may also
contribute to the sufficient transportation of Ag-captured DCs to
the draining LN. The mechanism of how laser illumination
enhances the motility of APCs is not known at present but we offer
the following rationale. In the skin, the initial lymphatic vessels are
blind-end structures with wide lamina and thin walls. These initial
lymphatic vessels drain excess fluid and solutes from the interstitial
space and pass them to LN via lymphatic ducts. The draining
process is extremely slow under normal physiological conditions
but it can be increased as many as 10 times by inflammation or
fever-range hyperthermia [26;27]. The interstitial space consists of
a complex microarchitecture comprising fibrillar proteins and
proteoglycans and offers the major barrier to molecular transport
through the interstitium. Brief laser illumination may transiently
alter the interstitial microarchitecture and increase the permeabil-
ity and flow of interstitial macromolecules or cells to lymphatic
capillaries as a result of photothermal and photomechanical
effects. A fast interstitial flow may result in an increase in the
number of Ag
+DCs significantly not only in the 1u draining LN
but also the 2u draining LN, due to increased lymphatic migration
of Ag
+DCs as well as a flow of free antigen from the skin to the
draining LN via afferent lymphatic vessel. The latter may account
primarily for the high number of Ag
+DCs in the secondary
draining LNs where free antigen from the skin was taken up by
residue DCs.
A study reported in Russian that cutaneous laser exposure
enhanced humoral immunity elicited by influenza vaccine
delivered intradermally [28]. Those studies used a copper vapor
laser that emitted a train of nanosecond pulses simultaneously at
two wavelengths, 510 nm and 578 nm. Our laser emits a similar
pulse train at the wavelength of 532 nm. Russian investigators
used substantially higher laser power and density (0.6 W and
3 W/cm2) and longer exposure time (3 min) than we did (0.3 W,
0.78 W/cm2 and 2 min, respectively), with similar exposure spot
sizes. The higher laser power and density stimulated persistent
inflammation for about one month and production of extracellular
HSP70 at the site of laser illumination [28]. In contrast, laser
exposure in our study did not induce a significant inflammatory
response as measured by the level of TNF-a, IL-6, IL-1b or CCL2
production. We also did not find an increase in either extracellular
or intracellular level of HSP70 in the homogenate of laser-exposed
skin over controls (data not shown). To the best of our knowledge,
we report here the first non-inflammatory vaccine adjuvant, which
can be potentially used to boost either Th1 or Th2 immune
responses dependent of the nature of a given vaccine or the
presence of other adjuvants.
To date, only two adjuvants (alum and MPL) have been
approved for human use in the US, despite the fact that many
potent vaccine adjuvants have been developed in animal studies.
The major issue with the use of adjuvants for human vaccines is
the concern on the potential toxicity and adverse side-effects of
most of the adjuvant formulations since prophylactic vaccines are
used to prevent illness, not treat diseases and much more stringent
regulation is applied. LVA stands out as a unique technology and
it is simple, convenient, risk-free, and cost-effective for vaccine
dose-sparing and should thus warrant a further test in the clinic
soon. The technology can potentially result in savings of a billion
dollars a year in season flu vaccines alone and reduce the burden
on the manufacturer of a new flu vaccine that is needed in
sufficient quantity in a short time in an event of an outbreak of a
new flu viral strain or pandemic.
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